Mr. George Reznik reports

LIGHT AI STRENGTHENS INTELLECTUAL PROPERTY PORTFOLIO WITH TWO NEW EUROPEAN PATENTS

Light AI Inc. has expanded its patent portfolio with the addition of two new European-based patents pertaining to the company's proprietary technology: one European patent validated in the United Kingdom and Spain, with another utility patent covering 17 European countries.

Light AI's proprietary technology platform is an app-based solution and is core to the advancement of patient management as it requires no swabs, lab tests or propriety hardware of any kind. The platform's cloud-based architecture enables access from smart devices such as smart phones and tablets commonly available in medical practices.

The platform, which is part of a suite of health and diagnostic wellness offerings, is designed to apply assistive AI (artificial intelligence) algorithms to smart phone images, starting with oropharynx images to identify strep A in seconds. The long-term vision is for the platform to identify a wide range of throat, eye, skin and other medical conditions through the company's AI-oriented platform.

"Securing these patents marks a pivotal step in our global expansion strategy and helps pave the way for our commercialization launch in Europe," said Peter Whitehead, chief executive officer of Light AI. "As demand for advanced medical technologies and newer solutions continues to rise across European and global health care systems, these patents not only strengthen our IP [intellectual property] portfolio but also position us to deliver innovative solutions at scale in one of the world's most regulated and high-potential markets in future. We are building an IP moat to fortify Light AI's first-mover advantage in this space."

Light AI's technology has been issued three U.S. patents, three European patents and one Australian patent to date pertaining to the image processing of streptococcal infection in pharyngitis subjects as follows:

• United States:
  • Patent No. 11,369,318;
  • Patent No. 11,602,312;
  • Patent No. 12,148,150;
• Australia:
  • Patent No. 2019357949;
• European Union:
  • Patent No. 3864669.

About Light AI Inc.

Light AI is a technology company focused on developing artificial intelligence health diagnostic solutions. Light AI is developing a technology platform that represents the next generation of patient management: It applies AI algorithms to smart phone images -- starting with images of strep A -- to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind; its hardware platform is the 4.5 billion smart phones that exist in the world today. Light AI is at the forefront of developing innovative diagnostic solutions aimed at improving health care delivery worldwide. Its cutting-edge AI-powered technology offers rapid, accurate and cost-effective diagnostic tools designed to address critical health care challenges.

In pre-FDA (U.S. Food and Drug Administration) validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A streptococcus (GAS). The algorithm achieved a 96.57-per-cent accuracy rate and attained a negative predictive value of 100 per cent, indicating its high reliability in confirming the absence of streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as rheumatic heart disease (RHD), which imposes a global economic burden exceeding $1- trillion annually. Light AI's technology offers a significant advancement in the accurate and timely diagnosis of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smart phone images can be expanded to other throat conditions as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smart phone with AI in the cloud to create a digital clinical lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time- consuming imaging or lab processes.

We seek Safe Harbor.